Please assess the completion status of the following clinical trial:

Trial Title: Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female greater than or equal to (≥) 18 years of age and less than or equal to (≤) 75 years of age.~2. CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery).~3. PE symptom duration ≤14 days.~4. Submassive PE: RV/LV diameter ≥ 0.9 from CTA and hemodynamically stable. For Participants in UK Sites: Submassive PE: RV/LV diameter ≥ 0.9 from CTA, hemodynamically stable and an elevated biomarker.~5. Must be treated within 48 hours of diagnosis of PE by CTA.~6. Signed Informed consent obtained from subject or Legally Authorized Representative.~Exclusion Criteria:~1. Stroke or transient ischemic attack (TIA), head trauma, or other active intracranial or intraspinal disease within one year.~2. Recent (within one month) or active bleeding from a major organ.~3. Major surgery within seven days of screening for study enrollment.~4. Clinician deems the subject high-risk for catastrophic bleeding.~5. History of heparin-induced thrombocytopenia (HIT).~6. Catheter-based pharmacomechanical treatment for PE within 3 days of study enrollment.~7. Systolic blood pressure (SBP) less than 90 mm Hg and/or use of vasopressors.~8. Cardiac arrest (including pulseless electrical activity and asystole) requiring active cardiopulmonary resuscitation (CPR).~9. Evidence of irreversible neurological compromise.~10. Life expectancy \< one year. For Participants in UK Sites: Life expectancy \< one year or enrollment in hospice care.~11. Use of thrombolytics or glycoprotein IIb/IIIa antagonists within 3 days prior to inclusion in the study.~12. Out-of-Range Laboratory Values: Hematocrit \< 30%, Platelets \< 100 thousand/microliter (μL), International normalized ratio (INR) \> 3.~13. Creatinine outside the normal range for the treating institution.~14. Participant is pregnant (positive pregnancy test; women of childbearing capacity must be tested) or breast feeding.~15. Active cancer (metastatic, progressive, or treated within the last 6 months). Exception: participants with non-melanoma primary skin cancers are eligible to participate in the study.~16. Known allergy, hypersensitivity, or thrombocytopenia from heparin, r-tPA, or iodinated contrast except for mild-moderate contrast allergies for which steroid pre-medication can be used.~17. History of any hematologic disease potentially involving abnormal platelet number or function.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- APT/2 Hours-r-tPA/2 mg/hr/Catheter (Type: EXPERIMENTAL): A total of 4 or 8 mg r-tPA (as 2 mg/hour \[hr\]/catheter) will be delivered through Ekosonic® Endovascular Device (EKOS) ultrasonic infusion catheter for 2 hrs.
- APT/4 Hours-r-tPA/1 mg/hr/Catheter (Type: EXPERIMENTAL): A total of 4 or 8 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 4 hrs.
- APT/6 Hours-r-tPA/1 mg/hr/Catheter (Type: EXPERIMENTAL): A total of 6 or 12 mg r-tPA (as 1 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.
- APT/6 Hours-r-tPA/2 mg/hr/Catheter (Type: EXPERIMENTAL): A total of 12 or 24 mg r-tPA (as 2 mg/hr/catheter) will be delivered through EKOS ultrasonic infusion catheter for 6 hrs.

Based on this trial design, predict the completion outcome and termination type (if applicable).